Literature DB >> 12427369

Gut inflammation and spondyloarthropathies.

Filip De Keyser1, Dominique Baeten, Filip Van den Bosch, Martine De Vos, Claude Cuvelier, Herman Mielants, Eric Veys.   

Abstract

Spondyloarthropathies (SpA) are a group of related disorders with common clinical and genetic characteristics. The prototype disease in this group is ankylosing spondylitis; other entities include reactive arthritis, psoriatic arthritis, and arthritis in patients with inflammatory bowel disease. Over recent years, there has been a special interest in the relation between spondylitis/synovitis and gut inflammation in patients with SpA. Two thirds of patients with undifferentiated SpA show histologic signs of gut inflammation, and a fraction of these patients go on to develop clinically overt Crohn's disease. In this review, the authors will focus on 1) the growing evidence that has been provided that gut inflammation in SpA is immunologically related to Crohn's disease, based on the molecular characterization of the inflammation (lymphocyte homing markers and ligands, T cell cytokines, macrophage markers, and serology); and 2) on the therapeutic implications resulting from this concept. The recent introduction and positioning of anti-tumor necrosis factor-alpha therapy in patients with ankylosing spondylitis and other types of SpA is, in large part, based on this concept.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427369     DOI: 10.1007/s11926-002-0061-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  63 in total

1.  Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.

Authors:  S Vermeire; S Joossens; M Peeters; F Monsuur; G Marien; X Bossuyt; P Groenen; R Vlietinck; P Rutgeerts
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

2.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

3.  Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage.

Authors:  P Demetter; M De Vos; N Van Damme; D Baeten; D Elewaut; S Vermeulen; M Mareel; G Bullock; H Mielants; G Verbruggen; F De Keyser; E M Veys; C A Cuvelier
Journal:  Am J Clin Pathol       Date:  2000-09       Impact factor: 2.493

4.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

5.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors:  U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

6.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

Authors:  P E Hesterberg; D Winsor-Hines; M J Briskin; D Soler-Ferran; C Merrill; C R Mackay; W Newman; D J Ringler
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.

Authors:  Dominique Baeten; Pieter Demetter; Claude A Cuvelier; Elli Kruithof; Nancy Van Damme; Martine De Vos; Eric M Veys; Filip De Keyser
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

9.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

10.  The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects.

Authors:  H Mielants; E M Veys; M De Vos; C Cuvelier; S Goemaere; L De Clercq; L Schatteman; D Elewaut
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

View more
  14 in total

1.  COX 2 inhibition and bowel strictures.

Authors:  L P Maiden; I Bjarnason
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Osteoporosis: a paradox in ankylosing spondylitis.

Authors:  Shea Carter; Rik J Lories
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

3.  Experimental colitis does not increase the prevalence of ANKENT, a spontaneous joint disease in mice.

Authors:  J Capková; R Stepánková; T Hudcovic; J Sinkora; Z Reháková
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

Review 4.  Update on ankylosing spondylitis: current concepts in pathogenesis.

Authors:  Judith A Smith
Journal:  Curr Allergy Asthma Rep       Date:  2015-01       Impact factor: 4.806

5.  Gastrointestinal manifestations in systemic autoimmune diseases.

Authors:  M Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-01

Review 6.  [Enteropathic arthritis: water in the intestines, fire in the joints].

Authors:  M Ronneberger
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

7.  The colon in patients with ankylosing spondylitis and in normal controls in Bangladesh: a macroscopic and microscopic study.

Authors:  Md Nazrul Islam; Mir Mahfuzul Hoque Chowdhury; Syed Atiqul Haq; Mohammad Kamal; Anwarul Kabir; Mahmud Hasan; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2009-10-21       Impact factor: 2.980

8.  The clinical significance of focal enhanced gastritis in adults with isolated ileitis of the terminal ileum.

Authors:  Amber A Petrolla; Jeffry A Katz; Wei Xin
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527

Review 9.  Gastrointestinal lesions associated with spondyloarthropathies.

Authors:  Ambrogio Orlando; Sara Renna; Giovanni Perricone; Mario Cottone
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

10.  Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy.

Authors:  Sinead Brophy; Claire L Burrows; Caroline Brooks; Michael B Gravenor; Stefan Siebert; Stephen J Allen
Journal:  BMC Musculoskelet Disord       Date:  2008-01-11       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.